Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanping Hu

Showing results (161-170 of 200) with videos related to

Pageof 20
Sort By:
Cell|July 9, 2024
All-RNA-mediated targeted gene integration in mammalian cells with rationally engineered R2 retrotransposonsYangcan Chen, Shengqiu Luo, Yanping Hu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2023
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLCLei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Journal of Hematology & Oncology|January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.
JAMA Oncology|April 1, 2021
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical TrialJie Wang, Shun Lu, Xinmin Yu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 TrialYun Fan, Jun Zhao, Qiming Wang, et al.
Nature Communications|December 6, 2025
Pangenome analyses of tea plants reveal structural variations driving gene expression alterations and agronomic trait diversificationLingling Tao, Junyan Zhu, Jianbing Hu, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Vaccine|February 25, 2025
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years oldOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Vaccines|February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialJuleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 TrialShun Lu, Jie Wang, Yan Yu, et al.
Pageof 20

Showing results (161-170 of 200) with videos related to

Sort By:
Pageof 20
Cell|July 9, 2024
All-RNA-mediated targeted gene integration in mammalian cells with rationally engineered R2 retrotransposonsYangcan Chen, Shengqiu Luo, Yanping Hu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2023
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLCLei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Journal of Hematology & Oncology|January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.
JAMA Oncology|April 1, 2021
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical TrialJie Wang, Shun Lu, Xinmin Yu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 TrialYun Fan, Jun Zhao, Qiming Wang, et al.
Nature Communications|December 6, 2025
Pangenome analyses of tea plants reveal structural variations driving gene expression alterations and agronomic trait diversificationLingling Tao, Junyan Zhu, Jianbing Hu, et al.
Infectious Diseases and Therapy|July 1, 2025
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 TrialOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Vaccine|February 25, 2025
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years oldOyeniyi Diya, Juleen Gayed, Francine S Lowry, et al.
Vaccines|February 24, 2024
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 TrialJuleen Gayed, Oyeniyi Diya, Francine S Lowry, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 25, 2021
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 TrialShun Lu, Jie Wang, Yan Yu, et al.
Pageof 20